Novel pyridine derivatives

Abstract

The invention relates to a compound of formula (I) wherein A and R 1 to R 4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

1 - 14 . (canceled) 
     
     
         15 . A compound selected from the group consisting of:
 3-cyclopropyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole;   3-tert-butyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;   (4S)-4-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,5-dihydro-1,3-oxazole;   2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4-ethyl-4,5-dihydro-1,3-oxazole;   2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;   3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;   5-(azetidin-3-yl)-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;   2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;   5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;   1-[6-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-4-(cyclopropylmethoxy)pyridin-3-yl]-6-oxa-1-azaspiro[3.3]heptane;   3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5,5-dimethyl-4H-1,3-oxazole;   5-tert-butyl-3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;   3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;   1-[3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;   3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;   3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole   3-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]oxetan-3-amine;   5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   2-(5-tert-butyl-1H-imidazol-2-yl)-5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine;   5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,3-oxazole;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-ethyl-4-methyl-1H-imidazol-5-one;   2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-(2-methylpropyl)-1H-imidazol-5-one;   2-[5-bromo-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;   1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]pyrrolidin-3-ol;   5-tert-butyl-3-[5-cyclopropyl-4-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;   7-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-7-azaspiro[3.4]octane;   5-tert-butyl-3-[5-cyclopropyl-4-(3,3-difluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;   4-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]morpholine;   5-tert-butyl-3-(5-cyclopropyl-4-pyrrolidin-1-ylpyridin-2-yl)-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxyazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;   6-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-6-azaspiro[3.3]heptane;   5-tert-butyl-3-[5-cyclopropyl-4-(oxan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(1-propan-2-ylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;   2-tert-butyl-5-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,3,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-(5-cyclopropyl-4-piperidin-3-yloxypyridin-2-yl)-1,2,4-oxadiazole;   5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;   3-[2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-5H-1,3-oxazol-4-yl]-5-methyl-1,2,4-oxadiazole; and   5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole;   or a pharmaceutically acceptable salt thereof.   
     
     
         16 . A compound selected from the group consisting of:
 5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;   5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole; and   3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole;   or a pharmaceutically acceptable salt thereof.   
     
     
         17 - 19 . (canceled) 
     
     
         20 . A pharmaceutical composition comprising a compound of  claim 15 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         21 - 25 . (canceled) 
     
     
         26 . A pharmaceutical composition comprising a compound of  claim 16 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         27 . A compound of  claim 15 , wherein the compound is
 2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole,   or a pharmaceutically acceptable salt thereof.   
     
     
         28 . A pharmaceutical composition comprising a compound of  claim 27 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         29 . A compound of  claim 15 , wherein the compound is
 2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5,5-dimethyl-4H-1,3-oxazole,   or a pharmaceutically acceptable salt thereof.   
     
     
         30 . A pharmaceutical composition comprising a compound of  claim 29 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         31 . A compound of  claim 15 , wherein the compound is
 5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole,   or a pharmaceutically acceptable salt thereof.   
     
     
         32 . A pharmaceutical composition comprising a compound of  claim 31 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier. 
     
     
         33 . A compound of  claim 15 , wherein the compound is
 5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole,   or a pharmaceutically acceptable salt thereof.   
     
     
         34 . A pharmaceutical composition comprising a compound of  claim 33 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.